NYSE: BIOBio Rad Laboratories Inc Stock
$341.06+4.14 (+1.23%)
Updated Oct 14, 2024
BIO Price
$341.06
Fair Value Price
N/A
Market Cap
$9.51B
52 Week Low
$261.59
52 Week High
$364.24
P/E
-7.2x
P/B
1.4x
P/S
3.03x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.56B
Earnings
-$1.33B
Gross Margin
54%
Operating Margin
-65.57%
Profit Margin
-51.7%
Debt to Equity
0.43
Operating Cash Flow
$346M
Beta
0.83
Next Earnings
Oct 24, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BIO Overview
Bio-Rad Laboratories, Inc. develops and manufactures specialized technological products for the life science research and clinical diagnostics markets. Offerings include instruments, software, consumables, reagents, and content for cell biology, gene expression, and protein purification. It also offers diagnostic products and systems used in the blood transfusion, diabetes monitoring, autoimmune, and infectious disease testing markets. The company was founded in 1952 and is based in Hercules, California.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BIO is good value based on its book value relative to its share price (1.4x), compared to the US Medical Devices industry average (4.1x)
P/B vs Industry Valuation
BIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more BIO due diligence checks available for Premium users.
Be the first to know about important BIO news, forecast changes, insider trades & much more!
BIO News
Valuation
BIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.2x
Industry
42.57x
Market
27.44x
BIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.4x
Industry
4.1x
BIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIO's financial health
Profit margin
Revenue
$638.5M
Net Income
-$2.2B
Profit Margin
-339.2%
BIO's Earnings (EBIT) of -$1.68B... subscribe to Premium to read more.
Interest Coverage Financials
BIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$9.7B
Liabilities
$2.9B
Debt to equity
0.43
BIO's short-term assets ($3.06B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIO's short-term assets ($3.06B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIO's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
BIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$97.6M
Investing
-$30.9M
Financing
-$96.6M
BIO's operating cash flow ($346.20M)... subscribe to Premium to read more.
Debt Coverage Financials
BIO vs Medical Device Stocks
Bio Rad Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.